Jeffrey M. Jonas - 15 Jun 2021 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role: Chief Innovation Officer, Director
Signature: /s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Jeffrey M. Jonas
Issuer symbol: SAGE
Transactions as of: 15 Jun 2021
Net transactions value: -$176,468
Form type: 4
Filing time: 17 Jun 2021, 09:13:30 UTC
Previous filing: 11 Jun 2021
Next filing: 23 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SAGE	Common Stock	Award	$0	+10,000	+18%	$0.000000	66,330	15 Jun 2021	Direct	F1
transaction	SAGE	Common Stock	Tax liability	$181,868	-3,093	-4.7%	$58.80	63,237	15 Jun 2021	Direct
transaction	SAGE	Common Stock	Options Exercise	$5,400	+12,000	+19%	$0.4500^*	75,237	16 Jun 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SAGE	Stock Option (Right to Buy)	Options Exercise	$0	-12,000	-20%	$0.000000	46,587	16 Jun 2021	Common Stock	12,000	$0.4500	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On March 25, 2020, the reporting person was granted Performance Stock Units (PSU) to acquire a total of 25,000 shares of common stock. The PSU vests upon the achievement of certain milestones, one of which was met on June 15, 2021, resulting in the vesting of the PSU as to 10,000 shares.
F2	The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on August 12, 2017.